Key facts
- Flomark’s last known valuation is $7.0M (Jun 2025).
- It has raised $1.9M; the latest was Later Stage VC ($1.2M) in Jun 2025.
- Notable investors include Innovate UK, Parkwalk Advisors, Venrex Investment Management, Keihanna Global Acceleration Program, WCS Nominees — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Flomark
- ·The full record, as it builds
Funding rounds
No funding rounds for Flomark are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Flomark
Developer of an IV administration drip technology designed to intuitively and reliably show the flow rate. The company's drip technology has a simple fluid level that shows the rate against a scale instead of the standard method of counting drops, enabling clinical staff to reduce the time taken to set infusion rates in comparison to traditional sets.
- Sector
- Healthcare
- HQ
- Chesham, United Kingdom
- Founded
- 2017
- Employees
- 2
- Website
- flomark.co.uk/
- Ownership
- Privately Held (backing)
Flomark doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Flomark shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Flomark in its N-PORT filings yet. We sweep new filings monthly.